Oncology is a perfect fit for the bundled payment model, because it evaluates the outcomes, patient satisfaction, and cost of an oncology episode, said Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ. She said that Horizon adopted the bundled payment model early to cope with New Jersey’s rising healthcare costs.
Oncology is a perfect fit for the bundled payment model, because it evaluates the outcomes, patient satisfaction, and cost of an oncology episode, said Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ. She said that Horizon adopted the bundled payment model early to cope with New Jersey’s rising healthcare costs.
Transcript (slightly modified)
How can episode-based, or bundled, payments improve value and quality in cancer care?
We believe that episode-based payment can improve payments in any type of model, any type of specialty, and oncology care is no different from that. As we look at the shift in changing from fee-for-service to value-based care, oncology fits that model perfectly because it does look at specific services and events that happen to a patient along their care continuum, so we have the opportunity at Horizon to evaluate the total cost of care that patient is receiving within the oncology episode, their outcomes, and then their overall patient satisfaction.
Adoption of bundled payments has so far been fairly slow. Why did Horizon Blue Cross Blue Shield jump in so quickly?
The episode payment model, the reform, it’s really an evolution and not a revolution. So being slow doesn’t surprise us or surprise me, we believe it will take time for those changes to take place. But Horizon knew that inevitably something had to change. New Jersey has the 2nd highest healthcare cost in the nation and we could not continue to just look at cost rising and not figure out ways to address that, and then we decided to build our models around patient satisfaction, quality of care, and then the total cost of care. So that’s the reason why Horizon jumped in, because we knew we wanted to be there as the ground was breaking and not at the end of the event.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Breast Cancer Outcomes Improved in States With Medicaid Expansion
October 24th 2024Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.
Read More